Key points from article :
Maxwell Biosciences recently secured a significant investment from David Evans Shaw, a prominent investor in biosciences, to advance their innovative antiviral drug program. Maxwell’s CLAROMER™ brand anti-infectives aim to target a broad spectrum of viruses, including HSV-1 and SARS-CoV-2. In collaboration with Dr. Gill Diamond from the University of Louisville and ten other researchers, Maxwell co-authored a study on the effectiveness of these anti-infectives, which was published in the peer-reviewed journal Pharmaceuticals.
The research showed that CLAROMER™ compounds effectively destroy viral structures by disrupting the virus's outer membrane and binding its DNA and RNA. Using cryo-electron microscopy, researchers observed the drug's mechanism in detail, revealing its direct virucidal action. In preclinical studies, CLAROMER™ compounds showed high efficacy against Hepatitis B and C, Influenza A, and all tested strains of SARS-CoV-2, while demonstrating safety in human tissue models at therapeutic doses.
Shaw’s investment will accelerate Maxwell’s development program for CLAROMER™ anti-infectives, beginning with topical applications to minimize systemic risks. Maxwell’s approach aims to target viral infections like recurrent herpes with a potentially optimal therapeutic window, allowing high efficacy without toxic effects. Over a decade of academic research supports the selectivity and effectiveness of Maxwell’s product candidates, making them a promising tool in the fight against evolving viral threats.
With Shaw’s backing, Maxwell is well-positioned to advance its mission of addressing critical global health needs. Shaw, renowned for his focus on social impact investments, cited the potential to benefit millions of patients as a motivating factor in his decision to support Maxwell. This partnership strengthens Maxwell’s path toward developing innovative treatments that could reshape antiviral therapies.
